medigraphic.com
ISSN 0188-2198 (Print)

2018, Number 2

Next >>

Rev Mex Cardiol 2018; 29 (2)

Carbohydrate and lipid disorders and adipokines levels in relation to body mass index in hypertensive patients

Ashcheulova T, Demydenko G, Ambrosova T, Kateryna K, Gerasimchuk N, Kochubiei K

Language: English
References: 27
Page: 74-82
PDF size: 276.66 Kb.


ABSTRACT

Obesity is considered as a valid risk factor for cardiovascular disease, due to the fact that the risk of morbidity and mortality from various causes in obese people is significantly higher. Exact mechanisms of metabolic disorders in hypertension with obesity is still discussible. The aim of the study – to determine the peculiarities of carbohydrate, lipid metabolism changes and activity of adipokines and interleukin-22, in patients with hypertension according to nutritional status. Methods: 80 patients (37 males and 43 females) with essential hypertension (EH) of average age 60.17 years were examined. Carbohydrate, lipid profiles, apolipoprotein B (apo B), tumor necrosis factor-α (TNF-α), plasminogen activator inhibitor-1 (PAI-1), adiponectin, interleukin-22 (IL-22) were estimated. Results: In patients with EH and obesity was found carbohydrates metabolism abnormalities, that was manifested as hyperinsulinemia, glucose and HbA1c levels elevation and insulin resistance (according to HOMA index). Lipid metabolism disorders were observed as valid increasing of triglycerides and apo B. Body mass index elevation was associated with progressive increasing of TNF-α and PAI-1 concentration with reducing of adiponectin level in the patients with EH. Positive relationships between TNF- and HbA1c, apo B; PAI-1 with glucose levels: negative correlation adiponectin with body mass and waist to hip ratio were detected in the patients with obesity associated (BMI ≥ 30 kg/m2) EH. Positive significant correlations between apo B and insulin levels, HOMA index, and TNF-α concentration were defined. IL-22 in overweigh and obese patients was significantly higher, correlates negatively with HDL-C. Conclusion: In patients with EH and obesity the adipokine dysfunction was revealed, that correlates with carbohydrate and lipid parameters that indicate increased proinflammatory and prothrombogenic processes.


REFERENCES

  1. WHO. Global health risks: mortality and burden of disease attributable to selected major risks. Geneva: World Health Organization; 2009. p. 70.

  2. Kotchen TA. Obesity-related hypertension: epidemiology, pathophysiology, and clinical management. Am J Hypertens. 2010; 23 (11): 1170-1108.

  3. Muntner P, He J, Chen J, Fonseca V, Whelton PK. Prevalence of non-traditional cardiovascular disease risk factors among persons with impaired fasting glucose, impaired glucose tolerance, diabetes, and the metabolic syndrome: analysis of the Third National Health and Nutrition Examination Survey (NHANES III). Ann Epidemiol. 2004; 14 (9): 686-695.

  4. Sattar N, McConnachie A, Shaper AG, Blauw GJ, Buckley BM, de Craen AJ et al. Can metabolic syndrome usefully predict cardiovascular disease and diabetes? Outcome data from two prospective studies. Lancet. 2008; 371 (9628): 1927-1935.

  5. Jensen MD. Role of body fat distribution and the metabolic complications of obesity. J Clin Endocrinol Metab. 2008; 93 (11 Suppl 1): S57-S63.

  6. Yiannikouris F, Gupte M, Putnam K, Cassis L. Adipokines and blood pressure control. Curr Opin Nephrol Hypertens. 2010; 19 (2): 195-200.

  7. Rasouli N, Kern PA. Adipocytokines and the metabolic complications of obesity. J Clin Endocrinol Metab. 2008; 93 (11 Suppl 1): S64-S73.

  8. Dalmas E, Donath MY. A role for interleukin-22 in the alleviation of metabolic syndrome. Nat Med. 2014; 20 (12): 1379-1381.

  9. Dudakov JA, Hanash AM, van den Brink MR. Interleukin-22: immunobiology and pathology. Annu Rev Immunol. 2015; 33: 747-785.

  10. Mancia G, Laurent S, Agabiti E. 2013 guidelines for the management of arterial hypertension: Task Force document. Eur Heart J. 2013; 34: 2159-2219.

  11. Task Force Members, Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts): Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur J Prev Cardiol. 2016; 23 (11): NP1-NP96.

  12. Stepien M, Stepien A, Banach M, Wlazel RN, Paradowski M, Rizzo M et al. New obesity indices and adipokines in normotensive patients and patients with hypertension: comparative pilot analysis. Angiology. 2014; 65 (4): 333-342.

  13. Stępień M, Stępień A, Wlazeł RN, Paradowski M, Banach M, Rysz J. Obesity indices and inflammatory markers in obese non-diabetic normo- and hypertensive patients: a comparative pilot study. Lipids Health Dis. 2014; 13: 29.

  14. Nakamura K, Fuster JJ, Walsh K. Adipokines: a link between obesity and cardiovascular disease. J Cardiol. 2014; 63 (4): 250-259.

  15. Stepien M, Stepien A, Wlazel RN, Paradowski M, Rizzo M, Banach M et al. Predictors of insulin resistance in patients with obesity: a pilot study. Angiology. 2014; 65 (1): 22-30.

  16. Wanders D, Plaisance EP, Judd RL. Pharmacological effects of lipid-lowering drugs on circulating adipokines. World J Diabetes. 2010; 1 (4): 116-128.

  17. Mattu HS, Randeva HS. Role of adipokines in cardiovascular disease. J Endocrinol. 2013; 216 (1): T17-T36.

  18. Antoniades C, Antonopoulos AS, Tousoulis D, Stefanadis C. Adiponectin: from obesity to cardiovascular disease. Obes Rev. 2009; 10 (3): 269-279.

  19. Mancuso P. The role of adipokines in chronic inflammation. Immunotargets Ther. 2016; 5: 47-56.

  20. Chow WS, Cheung BM, Tso AW, Xu A, Wat NM, Fong CH et al. Hypoadiponectinemia as a predictor for the development of hypertension: a 5-year prospective study. Hypertension. 2007; 49 (6): 1455-1461.

  21. Correia ML, Haynes WG. A role for plasminogen activator inhibitor-1 in obesity: from pie to PAI? Arterioscler Thromb Vasc Biol. 2006; 26 (10): 2183-2185.

  22. Yajima K, Shimada A, Hirose H, Oikawa Y, Yamada S, Meguro S et al. Effect on the atherogenic marker plasminogen activator inhibitor type-1 of addition of the ACE inhibitor imidapril to angiotensin II type 1 receptor antagonist therapy in hypertensive patients with abnormal glucose metabolism: a prospective cohort study in primary care. Clin Drug Investig. 2009; 29 (12): 811-819.

  23. Yang L, Zhang Y, Wang L, Fan F, Zhu L, Li Z et al. Amelioration of high fat diet induced liver lipogenesis and hepatic steatosis by interleukin-22. J Hepatol. 2010; 53 (2): 339-347.

  24. Wolk K, Witte E, Witte K, Warszawska K, Sabat R. Biology of interleukin-22. Semin Immunopathol. 2010; 32 (1): 17-31.

  25. Herder C, Kannenberg JM, Carstensen-Kirberg M, Huth C, Meisinger C, Koenig W et al. Serum levels of interleukin-22, cardiometabolic risk factors and incident type 2 diabetes: KORA F4/FF4 study. Cardiovasc Diabetol. 2017; 16 (1): 17.

  26. Sabat R, Wolk K. Deciphering the role of interleukin-22 in metabolic alterations. Cell Biosci. 2015; 5: 68.

  27. Gong F, Wu J, Zhou P, Zhang M, Liu J, Liu Y et al. Interleukin-22 might act as a double-edged sword in type 2 diabetes and coronary artery disease. Mediators Inflamm. 2016; 2016: 8254797.




2020     |     www.medigraphic.com